• Zahid Azam, Muhammad Shoaib, Masood Javed, Muhammad Adnan Sarwar, Hafeezullah Shaikh, and Nasir Khokhar.
• Prof. Zahid Azam, FCPS (Gastro); FCPS (Med); M.Sc (Clinical Research). Professor of Medicine & Gastroenterology, Gastroinstinal and Liver Practice (GILP) and Dow University of Health Sciences, Karachi, Pakistan.
• Pak J Med Sci. 2017 Jan 1; 33 (1): 485248-52.

ObjectiveThe uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 - 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens containing Sofosbuvir (Zoval) among Pakistani population with the rapid virologic response (RVR2/4 weeks) with HCV infections.MethodsThis is a multicenter open label prospective observational study. Patients suffering from chronic Hepatitis C infection received Sofosbuvir (Zoval) 400 mg plus ribavirin (with or without peg interferon) for 12/24 weeks. The interim results of this study were rapid virological response on week 4. Data was analyzed using SPSS version 21 for descriptive statistics.ResultsA total of 573 patients with HCV infection were included in the study. The mean age of patients was 46.07 ± 11.41 years. Out of 573 patients 535 (93.3%) were treatment naive, 26 (4.5%) were relapser, 7 (1.2%) were non-responders and 5 (1.0%) were partial responders. A rapid virologic response was reported in 563(98.2%) of patients with HCV infection after four weeks of treatment. The treatment was generally well tolerated.ConclusionSofosbuvir (Zoval) is effective and well tolerated in combination with ribavirin in HCV infected patients.

3 keywords...

hide…